AR086078A1 - Proteinas de fusion y vacunas de combinacion - Google Patents
Proteinas de fusion y vacunas de combinacionInfo
- Publication number
- AR086078A1 AR086078A1 ARP120101264A ARP120101264A AR086078A1 AR 086078 A1 AR086078 A1 AR 086078A1 AR P120101264 A ARP120101264 A AR P120101264A AR P120101264 A ARP120101264 A AR P120101264A AR 086078 A1 AR086078 A1 AR 086078A1
- Authority
- AR
- Argentina
- Prior art keywords
- protein
- haemophilus influenzae
- fusion proteins
- pila
- immunogenic fragment
- Prior art date
Links
- 102000037865 fusion proteins Human genes 0.000 title abstract 3
- 108020001507 fusion proteins Proteins 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 2
- 230000002163 immunogen Effects 0.000 abstract 6
- 241000606768 Haemophilus influenzae Species 0.000 abstract 5
- 229940047650 haemophilus influenzae Drugs 0.000 abstract 5
- 101710204837 Envelope small membrane protein Proteins 0.000 abstract 4
- 101710088839 Replication initiation protein Proteins 0.000 abstract 4
- 239000012634 fragment Substances 0.000 abstract 4
- 241001377010 Pila Species 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 3
- 108010076504 Protein Sorting Signals Proteins 0.000 abstract 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pulmonology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente se refiere a composiciones que comprenden Proteína E y Pilina A de Haemophilus influenzae. De una manera más particular, la presente solicitud se refiere a proteínas de fusión y a composiciones inmunogénicas que comprenden Proteína E y PilA, a vacunas que comprenden estas composiciones inmunogénicas, y a los usos terapéuticos de las mismas.Reivindicación 1: Una proteína de fusión de la fórmula (1) (X)m-(R1)n-A-(Y)o-B-(Z)p (1) en donde: X es un péptido de señal o MHHHHHH (SEQ ID Nº 2); m es 0 ó 1; R1 es un aminoácido; n es 0, 1, 2, 3, 4, 5 ó 6; A es la Proteína E a partir de Haemophilus influenzae o un fragmento inmunogénico de la misma, o PilA a partir de Haemophilus influenzae o un fragmento inmunogénico de la misma; Y se selecciona a partir del grupo que consiste en GG, SG, SS, GGG y (G)h en donde h es 4, 5, 6, 7, 8, 9, ó 10; o es 0 ó 1; B es PilA a partir de Haemophilus influenzae o un fragmento inmunogénico de la misma, o Proteína E a partir de Haemophilus influenzae o un fragmento inmunogénico de la misma; Z es GGHHHHHH (SEQ ID Nº 3); y p es 0 ó 1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161474779P | 2011-04-13 | 2011-04-13 | |
| US201161534012P | 2011-09-13 | 2011-09-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR086078A1 true AR086078A1 (es) | 2013-11-20 |
Family
ID=47008755
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120101264A AR086078A1 (es) | 2011-04-13 | 2012-04-12 | Proteinas de fusion y vacunas de combinacion |
Country Status (36)
| Country | Link |
|---|---|
| US (7) | US8945577B2 (es) |
| EP (2) | EP3321287B1 (es) |
| JP (1) | JP6196963B2 (es) |
| KR (1) | KR101999673B1 (es) |
| CN (3) | CN107522788A (es) |
| AR (1) | AR086078A1 (es) |
| AU (1) | AU2012243412C1 (es) |
| BR (1) | BR112013026175B1 (es) |
| CA (1) | CA2830786C (es) |
| CL (1) | CL2013002937A1 (es) |
| CO (1) | CO6781540A2 (es) |
| CR (1) | CR20130529A (es) |
| CY (2) | CY1120319T1 (es) |
| DK (2) | DK3321287T3 (es) |
| DO (1) | DOP2013000235A (es) |
| EA (1) | EA031580B1 (es) |
| ES (2) | ES2776369T3 (es) |
| HR (2) | HRP20180216T1 (es) |
| HU (2) | HUE048848T2 (es) |
| IL (2) | IL271862B (es) |
| LT (2) | LT2707393T (es) |
| MA (1) | MA35110B1 (es) |
| ME (1) | ME02995B (es) |
| MX (1) | MX350013B (es) |
| PE (1) | PE20140986A1 (es) |
| PH (1) | PH12013502121A1 (es) |
| PL (2) | PL3321287T3 (es) |
| PT (2) | PT2707393T (es) |
| RS (1) | RS56903B1 (es) |
| SG (2) | SG193906A1 (es) |
| SI (2) | SI2707393T1 (es) |
| SM (1) | SMT201800125T1 (es) |
| TW (1) | TW201302779A (es) |
| UY (1) | UY34017A (es) |
| WO (1) | WO2012139225A1 (es) |
| ZA (1) | ZA201307118B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201302779A (zh) | 2011-04-13 | 2013-01-16 | Glaxosmithkline Biolog Sa | 融合蛋白質及組合疫苗 |
| WO2014060383A1 (en) * | 2012-10-17 | 2014-04-24 | Glaxosmithkline Biologicals S.A. | Immunogenic composition comprising 1 or more streptococcus pneumoniae capsular saccharide conjugates and a protein component comprising protein e and/or pila fromhaemophilus influenzae. |
| GB201218660D0 (en) | 2012-10-17 | 2012-11-28 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| PT3051957T (pt) | 2013-09-30 | 2019-09-23 | Iaf Science Holdings Ltd | Produto para mastigar e processo para preparar o mesmo |
| TW201620927A (zh) | 2014-02-24 | 2016-06-16 | 葛蘭素史密斯克藍生物品公司 | Ｕｓｐａ２蛋白質構築體及其用途 |
| WO2016115522A2 (en) * | 2015-01-16 | 2016-07-21 | University Of Kentucky Research Foundation | Lipid bilayer-integrated spp1 connector protein nanopore and spp1 connector protein variants for use as lipid bilayer-integrated nanopore |
| CN105175549B (zh) * | 2015-09-30 | 2019-08-16 | 康希诺生物股份公司 | 一种流感嗜血杆菌融合蛋白及其构建方法与应用 |
| GB201621686D0 (en) | 2016-12-20 | 2017-02-01 | Glaxosmithkline Biologicals Sa | Novel methods for inducing an immune response |
| WO2018178264A1 (en) | 2017-03-31 | 2018-10-04 | Glaxosmithkline Intellectual Property Development Limited | Immunogenic composition, use and method of treatment |
| WO2018178265A1 (en) | 2017-03-31 | 2018-10-04 | Glaxosmithkline Intellectual Property Development Limited | Immunogenic composition, use and method of treatment |
| IE87414B1 (en) | 2017-05-30 | 2023-07-19 | Glaxosmithkline Biologicals Sa | Novel methods for manufacturing an adjuvant |
| EP3641808A1 (en) | 2017-08-14 | 2020-04-29 | GlaxoSmithKline Biologicals S.A. | Methods of boosting immune responses |
| CN107602697B (zh) * | 2017-08-29 | 2020-05-05 | 杭州医学院 | 一种治疗流感嗜血杆菌引起鼻窦炎的血清及该血清的应用 |
| CN111670044A (zh) | 2017-12-01 | 2020-09-15 | 葛兰素史密丝克莱恩生物有限公司 | 皂苷纯化 |
| JP7426953B2 (ja) * | 2018-06-19 | 2024-02-02 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物 |
| WO2020030572A1 (en) | 2018-08-07 | 2020-02-13 | Glaxosmithkline Biologicals Sa | Processes and vaccines |
| WO2020109365A1 (en) | 2018-11-29 | 2020-06-04 | Glaxosmithkline Biologicals Sa | Methods for manufacturing an adjuvant |
| CN110540597B (zh) * | 2018-12-20 | 2021-04-30 | 湖北工业大学 | 基于流感嗜血杆菌表面蛋白的乳胶微球免疫层析试纸的制备方法 |
| CN110540598B (zh) * | 2018-12-20 | 2021-04-30 | 湖北工业大学 | 基于流感嗜血杆菌表面蛋白抗体的流感嗜血杆菌Elisa检测试剂盒及制备方法 |
| WO2020174044A1 (en) | 2019-02-27 | 2020-09-03 | Evaxion Biotech Aps | Vaccines targeting h. influenzae |
| US20220221455A1 (en) | 2019-04-18 | 2022-07-14 | Glaxosmithkline Biologicals Sa | Antigen binding proteins and assays |
| BR112021024363A2 (pt) | 2019-06-05 | 2022-03-22 | Glaxosmithkline Biologicals Sa | Purificação de saponina |
| JP2022543281A (ja) * | 2019-08-05 | 2022-10-11 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物 |
| WO2021023692A1 (en) | 2019-08-05 | 2021-02-11 | Glaxosmithkline Biologicals Sa | Process for preparing a composition comprising a protein d polypeptide |
| WO2022175423A1 (en) | 2021-02-22 | 2022-08-25 | Glaxosmithkline Biologicals Sa | Immunogenic composition, use and methods |
| KR20220142219A (ko) * | 2021-04-14 | 2022-10-21 | 한국생명공학연구원 | 장내 미생물에서 단백질 분비를 유도하는 신호서열 |
| EP4558170A1 (en) | 2022-07-19 | 2025-05-28 | GlaxoSmithKline Biologicals S.A. | Continuous process for vaccine production |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE454403B (sv) | 1984-05-30 | 1988-05-02 | Alfa Laval Agri Int | Anvendning av ett cellyteprotein med fibronektin-, fibrinogen-, kollagen-, och/eller lamininbindande egenskaper vid framstellning av sarbehandlingsmedel |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| AU648251B2 (en) * | 1989-03-09 | 1994-04-21 | Wyeth Holdings Corporation | Vaccines for nontypable haemophilus influenzae |
| SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
| KR100278157B1 (ko) | 1992-06-25 | 2001-01-15 | 장 스테판느 | 보조약을 함유하는 백신 조성물 |
| CZ289476B6 (cs) | 1993-03-23 | 2002-01-16 | Smithkline Beecham Biologicals (S.A.) | Očkovací přípravek a způsob jeho výroby |
| GB9326253D0 (en) | 1993-12-23 | 1994-02-23 | Smithkline Beecham Biolog | Vaccines |
| CA2194761C (en) | 1994-07-15 | 2006-12-19 | Arthur M. Krieg | Immunomodulatory oligonucleotides |
| UA56132C2 (uk) | 1995-04-25 | 2003-05-15 | Смітклайн Бічем Байолоджікалс С.А. | Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини |
| US6440425B1 (en) | 1995-05-01 | 2002-08-27 | Aventis Pasteur Limited | High molecular weight major outer membrane protein of moraxella |
| AU696338B2 (en) | 1995-06-23 | 1998-09-10 | Smithkline Beecham Biologicals (Sa) | A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate |
| ATE497004T1 (de) | 1996-12-20 | 2011-02-15 | Univ Texas | Moraxella catarrhalis antigene uspa1 und uspa2 |
| CA2423487C (en) | 2000-09-26 | 2015-12-15 | Hybridon, Inc. | Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| BR0114403A (pt) | 2000-10-02 | 2004-02-17 | Shire Biochem Inc | Polipeptìdeos de "haemophilus influenzae" que podem ser usados para fins de profilaxia, diagnóstico e/ou terapia |
| US6942802B2 (en) | 2001-04-13 | 2005-09-13 | Wyeth Holdings Corporation | Removal of bacterial endotoxin in a protein solution by immobilized metal affinity chromatography |
| WO2003035836A2 (en) | 2001-10-24 | 2003-05-01 | Hybridon Inc. | Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends |
| GB0222764D0 (en) | 2002-10-02 | 2002-11-06 | Univ Bristol | Therapeutic peptide |
| CA2531698A1 (en) | 2003-07-09 | 2005-01-27 | Sentigen Biosciences, Inc. | Method for assaying protein-protein interaction |
| GB0410866D0 (en) | 2004-05-14 | 2004-06-16 | Chiron Srl | Haemophilius influenzae |
| BRPI0611534A2 (pt) * | 2005-05-12 | 2010-09-21 | Novartis Ag | genes e proteìnas da brachyspira hyodysenteriae e uso das mesmas para diagnose e terapia |
| AU2006268780B2 (en) * | 2005-07-08 | 2011-03-24 | University Of Zurich | Phage display using cotranslational translocation of fusion polypeptides |
| JP2009500037A (ja) * | 2005-07-08 | 2009-01-08 | ネイションワイド チルドレンズ ホスピタル， インコーポレイテッド | Ｈａｅｍｏｐｈｉｌｕｓｉｎｆｌｕｅｎｚａｅ誘発性疾患のためのキメラワクチン |
| NZ565651A (en) | 2005-08-10 | 2012-01-12 | Arne Forsgren Ab | Interaction of moraxella catarrhalis with epithelial cells, extracellular matrix proteins and the complement system |
| CN104436180B (zh) | 2006-01-17 | 2021-08-31 | 阿恩·福斯格伦 | 新的表面外露流感嗜血菌蛋白质(蛋白质E；pE) |
| GB2444903A (en) * | 2006-12-21 | 2008-06-25 | Secr Defence | Live Francisella vaccine, inactivated at gene FTT1564 |
| US8575314B2 (en) | 2008-06-20 | 2013-11-05 | National University Corporation Okayama University | Antibody against oxidized LDL/β2GPI complex and use of the same |
| TW201302779A (zh) | 2011-04-13 | 2013-01-16 | Glaxosmithkline Biolog Sa | 融合蛋白質及組合疫苗 |
-
2012
- 2012-04-11 TW TW101112896A patent/TW201302779A/zh unknown
- 2012-04-12 ES ES17201766T patent/ES2776369T3/es active Active
- 2012-04-12 PT PT127715407T patent/PT2707393T/pt unknown
- 2012-04-12 CN CN201710656150.1A patent/CN107522788A/zh active Pending
- 2012-04-12 BR BR112013026175-7A patent/BR112013026175B1/pt active IP Right Grant
- 2012-04-12 CN CN201710655782.6A patent/CN107383201A/zh active Pending
- 2012-04-12 PL PL17201766T patent/PL3321287T3/pl unknown
- 2012-04-12 EP EP17201766.7A patent/EP3321287B1/en active Active
- 2012-04-12 DK DK17201766.7T patent/DK3321287T3/da active
- 2012-04-12 JP JP2014504132A patent/JP6196963B2/ja active Active
- 2012-04-12 SI SI201231223T patent/SI2707393T1/en unknown
- 2012-04-12 SI SI201231775T patent/SI3321287T1/sl unknown
- 2012-04-12 SG SG2013068663A patent/SG193906A1/en unknown
- 2012-04-12 AR ARP120101264A patent/AR086078A1/es active IP Right Grant
- 2012-04-12 EA EA201391240A patent/EA031580B1/ru not_active IP Right Cessation
- 2012-04-12 US US14/110,857 patent/US8945577B2/en active Active
- 2012-04-12 MX MX2013011939A patent/MX350013B/es active IP Right Grant
- 2012-04-12 ES ES12771540.7T patent/ES2658512T3/es active Active
- 2012-04-12 KR KR1020137029993A patent/KR101999673B1/ko active Active
- 2012-04-12 SM SM20180125T patent/SMT201800125T1/it unknown
- 2012-04-12 HR HRP20180216TT patent/HRP20180216T1/hr unknown
- 2012-04-12 PH PH1/2013/502121A patent/PH12013502121A1/en unknown
- 2012-04-12 AU AU2012243412A patent/AU2012243412C1/en active Active
- 2012-04-12 EP EP12771540.7A patent/EP2707393B1/en active Active
- 2012-04-12 DK DK12771540.7T patent/DK2707393T3/da active
- 2012-04-12 PE PE2013002281A patent/PE20140986A1/es not_active Application Discontinuation
- 2012-04-12 IL IL271862A patent/IL271862B/en unknown
- 2012-04-12 SG SG10201602549WA patent/SG10201602549WA/en unknown
- 2012-04-12 PL PL12771540T patent/PL2707393T3/pl unknown
- 2012-04-12 HU HUE17201766A patent/HUE048848T2/hu unknown
- 2012-04-12 PT PT172017667T patent/PT3321287T/pt unknown
- 2012-04-12 LT LTEP12771540.7T patent/LT2707393T/lt unknown
- 2012-04-12 CN CN2012800180323A patent/CN103476799A/zh active Pending
- 2012-04-12 LT LTEP17201766.7T patent/LT3321287T/lt unknown
- 2012-04-12 UY UY0001034017A patent/UY34017A/es not_active Application Discontinuation
- 2012-04-12 RS RS20180176A patent/RS56903B1/sr unknown
- 2012-04-12 HU HUE12771540A patent/HUE036983T2/hu unknown
- 2012-04-12 WO PCT/CA2012/050236 patent/WO2012139225A1/en not_active Ceased
- 2012-04-12 CA CA2830786A patent/CA2830786C/en active Active
- 2012-04-12 ME MEP-2018-15A patent/ME02995B/me unknown
-
2013
- 2013-09-11 IL IL228344A patent/IL228344B/en active IP Right Grant
- 2013-09-20 ZA ZA2013/07118A patent/ZA201307118B/en unknown
- 2013-10-09 CO CO13240514A patent/CO6781540A2/es unknown
- 2013-10-10 DO DO2013000235A patent/DOP2013000235A/es unknown
- 2013-10-11 CL CL2013002937A patent/CL2013002937A1/es unknown
- 2013-10-14 CR CR20130529A patent/CR20130529A/es unknown
- 2013-11-08 MA MA36409A patent/MA35110B1/fr unknown
-
2014
- 2014-12-16 US US14/571,546 patent/US9296794B2/en active Active
- 2014-12-16 US US14/571,807 patent/US9409957B2/en active Active
-
2016
- 2016-02-18 US US15/046,908 patent/US10023616B2/en active Active
- 2016-06-30 US US15/197,952 patent/US10214569B2/en active Active
-
2018
- 2018-01-04 US US15/861,789 patent/US10730917B2/en active Active
- 2018-02-28 CY CY20181100257T patent/CY1120319T1/el unknown
-
2020
- 2020-03-13 CY CY20201100222T patent/CY1122824T1/el unknown
- 2020-03-20 HR HRP20200466TT patent/HRP20200466T1/hr unknown
- 2020-07-07 US US16/922,112 patent/US11198707B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR086078A1 (es) | Proteinas de fusion y vacunas de combinacion | |
| ES2563646T3 (es) | Composiciones y métodos relacionados con variantes de la proteína A (SpA) | |
| MX358725B (es) | Antigenos prostaticos de consenso, molecula de acido nucleico que los codifica y vacuna y usos que los comprenden. | |
| CY1119265T1 (el) | Κατασκευες νανοσωματων τρισθενους αντι ανθρωπινου αναπνευστικου συγκυτιακου ιου (hrsv) για την προληψη και/ή θεραπεια λοιμωξεων της αναπνευστικης οδου | |
| NZ710626A (en) | Pcsk9 vaccine | |
| RU2016146198A (ru) | Терапевтические dll4-связывающие белки | |
| CY1118856T1 (el) | Εμβολιο pcsk9 | |
| GT201300295A (es) | "composiciones que contienen, metodos que involucran, y usos de derivados de dolastatina unidos a aminoacidos no naturales" | |
| EA201391632A1 (ru) | Аминокислотные последовательности, направленные против il-17a, il-17f и/или il-17a/f, и содержащие их полипептиды | |
| CO6491045A2 (es) | Composiciones de proteina f de virus sincitial respiratorio (rsv) y metodos para producir las mismas | |
| PH12012502272A1 (en) | Biological materials related to her3 | |
| HRP20180282T1 (hr) | Imunoterapija na bazi indoleamin 2, 3-dioksigenaze | |
| AR081809A1 (es) | Composiciones farmaceuticas que comprenden un polipeptido que comprende al menos un motivo cxxc y antigenos heterologos y usos de las mismas | |
| MX344015B (es) | Vacunas y diagnostico para torque teno virus porcino. | |
| AR128395A2 (es) | Péptidos novedosos capaces de inducir la formación de anticuerpos contra pcsk9 | |
| WO2008124646A3 (en) | Use of amyloid proteins as vaccine scaffolds | |
| BR112015003947A2 (pt) | proteínas de fusão e métodos para tratar, prevenir ou melhorar dor | |
| RU2015119523A (ru) | Новый способ лечения повреждения спинного мозга с применением фрагмента hmgb1 | |
| BR112016013157A2 (pt) | peptídeos resistentes à protease | |
| WO2009024327A3 (en) | New proteins for use in human and animal staphylococcus infections | |
| HK1206763A1 (en) | Charged nutritive fragments, proteins and methods | |
| NZ596501A (en) | Casb7439 constructs | |
| HRP20220064T1 (hr) | Zglobno modificirani fragmenti protutijela i postupci za pripravu | |
| WO2013171661A3 (en) | Adjuvant formulations and methods | |
| NZ601980A (en) | Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |